- Home
- ADAP vs IGMS Comparison
ADAP vs IGMS Comparison
Compare ADAP & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- IGMS
- Stock Information
- Founded
- ADAP 2008
- IGMS 1993
- Country
- ADAP United Kingdom
- IGMS United States
- Employees
- ADAP N/A
- IGMS N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- IGMS Health Care
- Exchange
- ADAP Nasdaq
- IGMS Nasdaq
- Market Cap
- ADAP 71.6M
- IGMS 82.1M
- IPO Year
- ADAP 2015
- IGMS 2019
- Fundamental
- Price
- ADAP $0.24
- IGMS $1.22
- Analyst Decision
- ADAP Strong Buy
- IGMS Hold
- Analyst Count
- ADAP 5
- IGMS 8
- Target Price
- ADAP $1.83
- IGMS $6.14
- AVG Volume (30 Days)
- ADAP 2.6M
- IGMS 167.6K
- Earning Date
- ADAP 05-14-2025
- IGMS 05-07-2025
- Dividend Yield
- ADAP N/A
- IGMS N/A
- EPS Growth
- ADAP N/A
- IGMS N/A
- EPS
- ADAP N/A
- IGMS N/A
- Revenue
- ADAP $178,032,000.00
- IGMS $2,679,000.00
- Revenue This Year
- ADAP N/A
- IGMS $121.76
- Revenue Next Year
- ADAP $65.49
- IGMS $46.83
- P/E Ratio
- ADAP N/A
- IGMS N/A
- Revenue Growth
- ADAP 195.34
- IGMS 25.77
- 52 Week Low
- ADAP $0.20
- IGMS $0.92
- 52 Week High
- ADAP $1.48
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- ADAP 37.78
- IGMS 47.65
- Support Level
- ADAP $0.23
- IGMS $1.16
- Resistance Level
- ADAP $0.26
- IGMS $1.31
- Average True Range (ATR)
- ADAP 0.04
- IGMS 0.12
- MACD
- ADAP 0.01
- IGMS 0.03
- Stochastic Oscillator
- ADAP 31.85
- IGMS 76.92
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.